Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
Launched by PFIZER'S UPJOHN HAS MERGED WITH MYLAN TO FORM VIATRIS INC. · Sep 29, 2005
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male and female subjects greater than or equal to 18 years of age
- • Overactive bladder symptoms for at least 3 months
- • Previously treated with antimuscarinic OAB medications
- Exclusion Criteria:
- • Participation in any professionally coached sessions (RN, NP, PA or PT) teaching behavioral interventions
About Pfizer's Upjohn Has Merged With Mylan To Form Viatris Inc.
Viatris Inc. is a global healthcare company formed from the merger of Pfizer's Upjohn division and Mylan, dedicated to providing access to high-quality medicines, including generics and specialty pharmaceuticals. With a strong commitment to innovation and patient-centric solutions, Viatris leverages a diverse portfolio and extensive global reach to address the evolving healthcare needs of patients worldwide. The company aims to create sustainable healthcare solutions by combining expertise in pharmaceutical development, manufacturing, and distribution, ultimately enhancing patient outcomes and improving overall health systems.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Oceanside, California, United States
Orlando, Florida, United States
Little Rock, Arkansas, United States
Spokane, Washington, United States
Phoenix, Arizona, United States
Philadelphia, Pennsylvania, United States
Albany, New York, United States
Beverly Hills, California, United States
Sacramento, California, United States
Raleigh, North Carolina, United States
Albuquerque, New Mexico, United States
Poughkeepsie, New York, United States
Greensboro, North Carolina, United States
Modesto, California, United States
Tustin, California, United States
Garden City, New York, United States
Mission Viejo, California, United States
Wellington, Florida, United States
Torrance, California, United States
Bronx, New York, United States
Endwell, New York, United States
Milford, Massachusetts, United States
Saint Louis, Missouri, United States
Hickory, North Carolina, United States
Westhampton, New Jersey, United States
Bala Cynwyd, Pennsylvania, United States
Provo, Utah, United States
Mount Pleasant, South Carolina, United States
Woodstock, Vermont, United States
Sun Lakes, Arizona, United States
Buena Park, California, United States
Paramount, California, United States
Colorado Springs, Colorado, United States
Wheat Ridge, Colorado, United States
Hallandale Beach, Florida, United States
Libertyville, Illinois, United States
Mattoon, Illinois, United States
Newton, Kansas, United States
Manchester, Missouri, United States
Canton, Ohio, United States
Zanesville, Ohio, United States
Norman, Oklahoma, United States
Abington, Pennsylvania, United States
Camp Hill, Pennsylvania, United States
Williamsport, Pennsylvania, United States
Simpsonville, South Carolina, United States
Bartlett, Tennessee, United States
Johnson City, Tennessee, United States
New Tazewell, Tennessee, United States
Mountlake Terrace, Washington, United States
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials